High-yield points
- WHO 2021: pediatric HGG is not "pediatric GBM" .
- Four pediatric-type entities:
- DMG, H3 K27-altered: midline;
- H3 G34-mutant: hemispheric;
- H3/IDH-wildtype;
- infant-type hemispheric: RTK fusions.
- Grade III vs. IV ("anaplastic astrocytoma" vs. "GBM") doesn't predict survival in children .
- Histone mutations :
- Frequency: found in about a third of pediatric GBM.
- Exclusivity: mutually exclusive with IDH.
- Location: K27 is midline, and G34 is hemispheric.
- Surgery:
- GTR prolongs survival in hemispheric HGG (HR 0.29). STR is little better than biopsy.
- Midline tumors: no proven resection benefit .
- Always get tissue for molecular profiling.
- Chemoradiation:
- Temozolomide alone: 3-year EFS about 11% .
- Adding lomustine: about 22% .
- Bevacizumab: no benefit .
- Targetable alterations:
- BRAF V600: dabrafenib + trametinib, ORR 56%.
- NTRK: larotrectinib.
- ALK/ROS1/MET in infants.
- H3 K27M: ONC201, FDA-approved 2025.
- MMRD: checkpoint inhibitors .
- Infant HGG has a paradoxically better prognosis, especially when fusion-positive .
Landmark papers
- HERBY (Grill et al., J Clin Oncol 2018): a randomized phase II trial of bevacizumab in pediatric high-grade glioma. Median EFS was 8.2 months with bevacizumab vs 11.8 months without (HR 1.44, P = .13) .
- Extent of resection (Hatoum et al., JAMA Netw Open 2022): a meta-analysis of 37 studies (1,387 patients). GTR vs STR carried a risk of death of RR 0.69 at 1 year and RR 0.74 at 2 years .
Pediatric high-grade gliomas (pHGG) are biologically distinct from adult glioblastoma. They are driven by histone H3 mutations and by other alterations, rarely by IDH. The 2021 WHO classification therefore groups them as "pediatric-type diffuse high-grade gliomas" . Under it:
- "Glioblastoma" is no longer used for pediatric-type tumors.
- The "anaplastic" modifier was dropped.
- Grade III vs. IV: the old split between "anaplastic astrocytoma" and "GBM" carries no prognostic value in children .
Location, age and molecular class predict behavior better than histologic grade does.
WHO 2021 types and their biology
- Discovery of the histone mutations :
- Exome sequencing of 48 pediatric GBMs :
- H3F3A (H3.3) mutations in 31%, at K27M or G34R/V.
- H3.3–ATRX–DAXX pathway mutations in 44%.
- ATRX/DAXX mutated in 100% of G34 tumors.
- TP53 mutated in 54% overall.
- Distinct subgroups : K27 and G34 each define an epigenetic subgroup, mutually exclusive with IDH1, arising in separate anatomic compartments.
- Four pediatric-type diffuse HGGs :
1. Diffuse midline glioma (DMG), H3 K27-altered: - Where: thalamus, brainstem (pons) and spinal cord. - Molecular: H3 K27M or, alternatively, EZHIP overexpression; hence "altered," not "mutant." Partners include TP53, ACVR1, PDGFRA and EGFR. - Grade: 4. 2. Diffuse hemispheric glioma, H3 G34-mutant: - Where: the cerebral hemispheres. - Molecular: G34R/V with TP53 and ATRX. - Grade: 4. 3. Diffuse pediatric-type HGG, H3-wildtype and IDH-wildtype: - Molecular: defined by PDGFRA, MYCN or EGFR alterations and the methylome. 4. Infant-type hemispheric glioma: - Who: newborns and infants. - Molecular: receptor tyrosine kinase fusions (NTRK family, ALK, ROS1, MET).
- Adult-type IDH-mutant astrocytoma (now one type, graded 2–4) is seen in older adolescents. Keep it separate in your head from pediatric-type tumors .
- Meta-analysis of more than 1,000 pHGG and DIPG :
- Co-segregating partner events within each histone subgroup:
- FBXW7 loss in G34R/V;
- TOP3A rearrangements in H3.3 K27M;
- BCOR mutations in H3.1 K27M.
- Genomic aberrations increase with age.
- Infants are biologically distinct.
Special groups
- Infant HGG: better than it looks :
- Paradox: in infants, high-grade tumors do better, and low-grade tumors have higher mortality.
- Three groups :
- Group 1: hemispheric, ALK/ROS1/NTRK/MET; intermediate outcome.
- Group 2: hemispheric, RAS/MAPK; excellent outcome.
- Group 3: midline, RAS/MAPK; progresses rapidly.
- Fusions in 130 "intrinsic" infant HGGs under age 4 :
- ALK 31, NTRK1/2/3 21, ROS1 9, MET 4.
- Fusion-positive tumors have better outcomes and respond to targeted therapy.
- Diffuse midline glioma outside the pons:
- Location modifies the effect of K27M in a mixed-age series of 120 :
- Infratentorial: worse survival than H3-wildtype.
- Supratentorial (e.g., thalamic): no different from H3-wildtype.
- H3 K27M is associated with poor outcome in non-brainstem pHGG (HERBY) .
- Constitutional mismatch repair deficiency (biallelic MMRD) :
- Biology: produces hypermutant GBM with neoantigen loads far above other tumors.
- Checkpoint inhibition: nivolumab produced durable responses in two siblings with recurrent disease.
- Practice point: think of it in a child with café-au-lait spots, consanguinity, or a family history of early colorectal, hematologic or brain cancer, and test for it.
Surgery
- Maximal safe resection is the goal :
- Meta-analysis of 37 studies (1,387 patients) :
- GTR vs. STR, risk of death: RR 0.69 at 1 year and RR 0.74 at 2 years.
- STR vs. biopsy: no difference at 1 year (RR 0.82, P = .07), and a modest benefit at 2 years (RR 0.89).
- Individual patient data, 427 patients :
- Compared with GTR: STR (HR 1.91) and biopsy (HR 2.10) both shortened survival.
- STR vs. biopsy: no difference (HR 0.91).
- GTR benefit by location:
- hemispheric: HR 0.29;
- infratentorial: HR 0.44;
- midline: not significant (HR 0.63, P = .16).
- Practical reading:
- Hemispheric tumors: aim for GTR when it is safe. A subtotal debulking buys little over biopsy.
- Thalamic and other midline tumors: the goal is often tissue for molecular diagnosis (stereotactic biopsy) and relief of hydrocephalus. Aggressive resection has not been shown to help .
- Tissue matters: send for methylation profiling and sequencing. H3 status, fusions, BRAF V600 and MMR status change therapy .
- Central review in HERBY overturned the HGG diagnosis in 12.3% .
Adjuvant therapy
- Standard frame: focal radiotherapy (about 54–59.4 Gy) with temozolomide for children over about 3 years.
- ACNS0126: temozolomide alone failed :
- 3-year EFS 11% and OS 22%.
- No better than CCG-945: p = 0.98.
- MGMT overexpression predicted worse 2-year EFS (5% vs. 17%).
- ACNS0423 (RT + TMZ, then lomustine + TMZ) :
- 3-year EFS: 22% vs. 11% in ACNS0126.
- 1-year EFS: 0.49.
- Benefit was largest without GTR, in GBM, and with MGMT overexpression.
- HERBY: bevacizumab added nothing :
- Median EFS: 8.2 months with bevacizumab vs. 11.8 months without (HR 1.44, P = .13).
- Serious adverse events: more with bevacizumab (58% vs. 48%).
- Infants: radiation is avoided or delayed. Chemotherapy and, for fusion-positive tumors, targeted therapy are used .
Targeted therapy
- BRAF V600 (5–10% of pHGG): dabrafenib + trametinib in relapsed disease, 41 patients :
- ORR 56%;
- median DOR 22.2 months;
- median OS 32.8 months.
- NTRK fusions: larotrectinib in 33 primary CNS tumors, 19 of them HGG :
- ORR 30%, and 24-week disease control 73%.
- Tumor shrinkage: 82% of patients with measurable disease.
- 12-month OS: 85%.
- H3 K27M DMG: ONC201 (dordaviprone) :
- Integrated analysis of recurrent, non-pontine, non-spinal DMG (50 patients, 4 of them children) :
- ORR 20% (RANO-HGG), and 30% with combined HGG/LGG criteria.
- Median DOR: 11.2 months.
- Grade 3 treatment-related events: 20%.
- FDA accelerated approval, 6 August 2025: for patients 1 year and older with H3 K27M DMG progressing after prior therapy .
- Hypermutant (MMRD) tumors: checkpoint inhibitors .
Related topics
- Diffuse Midline Glioma, H3 K27-Altered: the H3 K27-altered midline entity in detail.
- DIPG: pontine glioma: biopsy and treatment.
- Supratentorial Low-Grade Glioma: the low-grade counterpart.
- Embryonal Brain Tumors: molecular HGG masquerading as CNS-PNET.
- Spinal Cord Gliomas: spinal high-grade and low-grade gliomas.
- Li-Fraumeni Syndrome (Germline TP53 Loss): germline TP53 predisposition.
References
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106. PMID 34185076. verified
- Varlet P, Le Teuff G, Le Deley MC, et al. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro Oncol 2020;22(1):116–127. doi:10.1093/neuonc/noz142. PMID 31419298. verified
- Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012;482(7384):226–231. doi:10.1038/nature10833. PMID 22286061. verified
- Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22(4):425–437. doi:10.1016/j.ccr.2012.08.024. PMID 23079654. verified
- Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520–537.e5. doi:10.1016/j.ccell.2017.08.017. PMID 28966033. verified
- Guerreiro Stucklin AS, Ryall S, Fukuoka K, et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019;10(1):4343. doi:10.1038/s41467-019-12187-5. PMID 31554817. verified
- Clarke M, Mackay A, Ismer B, et al. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov 2020;10(7):942–963. doi:10.1158/2159-8290.CD-19-1030. PMID 32238360. verified
- Wang L, Li Z, Zhang M, et al. H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Hum Pathol 2018;78:89–96. doi:10.1016/j.humpath.2018.04.015. PMID 29727696. verified
- Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 2016;34(19):2206–2211. doi:10.1200/JCO.2016.66.6552. PMID 27001570. verified
- Hatoum R, Chen JS, Lavergne P, et al. Extent of tumor resection and survival in pediatric patients with high-grade gliomas: a systematic review and meta-analysis. JAMA Netw Open 2022;5(8):e2226551. doi:10.1001/jamanetworkopen.2022.26551. PMID 35972743. verified
- Hargrave DR, Terashima K, Hara J, et al. Phase II trial of dabrafenib plus trametinib in relapsed/refractory BRAF V600-mutant pediatric high-grade glioma. J Clin Oncol 2023;41(33):5174–5183. doi:10.1200/JCO.23.00558. PMID 37643378. verified
- Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol 2022;24(6):997–1007. doi:10.1093/neuonc/noab274. PMID 34850167. verified
- Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011;13(3):317–323. doi:10.1093/neuonc/noq191. PMID 21339192. verified
- Jakacki RI, Cohen KJ, Buxton A, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol 2016;18(10):1442–1450. doi:10.1093/neuonc/now038. PMID 27006176. verified
- Grill J, Massimino M, Bouffet E, et al. Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol 2018;36(10):951–958. doi:10.1200/JCO.2017.76.0611. PMID 29412784. verified
- Arrillaga-Romany I, Gardner SL, Odia Y, et al. ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma. J Clin Oncol 2024;42(13):1542–1552. doi:10.1200/JCO.23.01134. PMID 38335473. verified
- Blair HA. Dordaviprone: first approval. Drugs 2026;86(1):101–109. doi:10.1007/s40265-025-02252-3. PMID 41138047. verified
Verification (2026-11-13): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts. The WHO 2021 type definitions (locations and genes) come from the full text of reference 1, since its abstract does not list them.
Caveats:
- The radiotherapy dose range, age thresholds for radiation, and the CMMRD clinical clues are standard teaching, not drawn from the cited abstracts.
- Reference 8 is a mixed adult–pediatric series (median age 27).
- The ONC201 data are mostly adult, and pontine tumors were excluded.
- The figure is an original schematic.